{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:33:25Z","timestamp":1788813205941,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02475-6","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T01:30:20Z","timestamp":1740619820000},"page":"1469-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5494-9580","authenticated-orcid":false,"given":"Daniela","family":"Sansone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Garino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gottero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Gauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Clerico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Corneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Di Noi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Rita","family":"Mainolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marafetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Matteoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella Libera","family":"Balbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Petraroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Chiara M.","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Oleandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2475_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88\u201398. https:\/\/doi.org\/10.1038\/nrendo.2017.151","journal-title":"Nat Rev Endocrinol"},{"key":"2475_CR2","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","volume":"1","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https:\/\/doi.org\/10.1038\/nrdp.2015.19","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"2475_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.hjr.0000368191.86614.5a","volume":"17","author":"S van Dieren","year":"2010","unstructured":"van Dieren S, Beulens JWJ, van der Schouw YT, Grobbee DE, Neal B (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17(Suppl 1):S3\u20138. https:\/\/doi.org\/10.1097\/01.hjr.0000368191.86614.5a","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2475_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.clinthera.2021.09.003","volume":"43","author":"J Meyers","year":"2021","unstructured":"Meyers J, Hoog M, Mody R, Yu M, Davis K (2021) The Health Care Resource utilization and costs among patients with type 2 diabetes and either Cardiovascular Disease or Cardiovascular Risk Factors an Analysis of a US Health Insurance Database. Clin Ther 43:1827\u20131842. https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.003","journal-title":"Clin Ther"},{"key":"2475_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/13696998.2023.2194802","volume":"26","author":"AV van Schoonhoven","year":"2023","unstructured":"van Schoonhoven AV, Sch\u00f6ttler MH, Sern\u00e9 EH, Schr\u00f6mbges PPG, Postma MJ, Boersma C (2023) The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the Netherlands. J Med Econ 26:547\u2013553. https:\/\/doi.org\/10.1080\/13696998.2023.2194802","journal-title":"J Med Econ"},{"key":"2475_CR6","first-page":"421","volume":"19","author":"R Li","year":"2013","unstructured":"Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, Crosson JC, Herman WH (2013) Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 19:421\u2013430","journal-title":"Am J Manag Care"},{"key":"2475_CR7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s13300-021-01060-8","volume":"12","author":"E Artime","year":"2021","unstructured":"Artime E, Romera I, D\u00edaz-Cerezo S, Delgado E (2021) Epidemiology and economic Burden of Cardiovascular Disease in patients with type 2 diabetes Mellitus in Spain: a systematic review. Diabetes Ther 12:1631\u20131659. https:\/\/doi.org\/10.1007\/s13300-021-01060-8","journal-title":"Diabetes Ther"},{"key":"2475_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","volume":"21","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH (2018) Economic Burden of Cardiovascular Disease in Type 2 diabetes: a systematic review. Value Health 21:881\u2013890. https:\/\/doi.org\/10.1016\/j.jval.2017.12.019","journal-title":"Value Health"},{"key":"2475_CR9","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"2475_CR10","unstructured":"International Diabetes Federation IDF Diabetes Atlas, 10th edn"},{"key":"2475_CR11","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669\u20132701. https:\/\/doi.org\/10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"key":"2475_CR12","doi-asserted-by":"publisher","first-page":"7839101","DOI":"10.1155\/2017\/7839101","volume":"2017","author":"D Huang","year":"2017","unstructured":"Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C (2017) Macrovascular complications in patients with diabetes and Prediabetes. Biomed Res Int 2017:7839101. https:\/\/doi.org\/10.1155\/2017\/7839101","journal-title":"Biomed Res Int"},{"key":"2475_CR13","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, Scientific Document Group ESC, Prescott E, Cosentino F, Abdelhamid M, Aboyans V, Antoniou S, Asteggiano R, Baumgartner I, Buccheri S, Bueno H, \u010celutkien\u0117 J, Chieffo A, Christersson C, Coats A, Cosyns B, Czerny M, Deaton C, Falk V, Ference BA, Filippatos G, Fisher M, Huikuri H, Ibanez B, Jaarsma T, James S, Khunti K, K\u00f8ber L, Koskinas KC, Lewis BS, L\u00f8chen M-L, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Parati G, Pasquet AA, Patrono C, Petersen SE, Piepoli MF, Rakisheva A, Rossello X, Rossing P, Ryd\u00e9n L, Standl E, Tokgozoglu L, Touyz RM, Visseren F, Volpe M, Vrints C, Witkowski A, Hazarapetyan L, Zirlik A, Rustamova Y, Van De Borne P, Sokolovi\u0107 \u0160, Gotcheva N, Milicic D, Agathangelou P, Vrabl\u00edk M, Schou M, Hasan-Ali H, Viigimaa M, Lautam\u00e4ki R, Aboyans V, Klimiashvili Z, Kelm M, Siasos G, Kiss RG, Libungan B, Durkan M, Zafrir B, Colivicchi F, Tundybayeva M, Byty\u00e7i I, Mirrakhimov E, Trusinskis K, Saad\u00e9 G, Badarien\u0117 J, Banu C-A, Magri CJ, Boskovic A, Hattaoui ME, Martens F, Bosevski M, Knudsen EC, Burchardt P, Fontes-Carvalho R, Vinereanu D, Mancini T, Beleslin B, Martinka E, Fras Z, Conde AC, Mellbin L, Carballo D, Bsata W, Mghaieth F, Gungor B, Mitchenko O, Wheatcroft S, Trigulova R, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, K\u00f8ber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossell\u00f3 X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 44:4043\u20134140.  https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"2475_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.rec.2020.04.007","volume":"73","author":"Cosentino","year":"2020","unstructured":"Cosentino et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Revista Espa\u00f1ola De Cardiolog\u00eda. (English Edition) 73:404. https:\/\/doi.org\/10.1016\/j.rec.2020.04.007","journal-title":"(English Edition)"},{"key":"2475_CR15","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee A (2024) Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes\u20142024. Diabetes Care 47(S158\u2013S178). https:\/\/doi.org\/10.2337\/dc24-S009","DOI":"10.2337\/dc24-S009"},{"key":"2475_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1056\/NEJMc1615712","volume":"376","author":"E Ipp","year":"2017","unstructured":"Ipp E, Genter P, Childress K (2017) Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 376:890\u2013891. https:\/\/doi.org\/10.1056\/NEJMc1615712","journal-title":"N Engl J Med"},{"key":"2475_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","volume":"81","author":"A Andersen","year":"2021","unstructured":"Andersen A, Knop FK, Vilsb\u00f8ll T (2021) A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs 81:1003\u20131030. https:\/\/doi.org\/10.1007\/s40265-021-01499-w","journal-title":"Drugs"},{"key":"2475_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","volume":"39","author":"KA Lyseng-Williamson","year":"2019","unstructured":"Lyseng-Williamson KA (2019) Glucagon-like Peptide-1 receptor agonists in type 2 diabetes: their Use and Differential features. Clin Drug Investig 39:805\u2013819. https:\/\/doi.org\/10.1007\/s40261-019-00826-0","journal-title":"Clin Drug Investig"},{"key":"2475_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jdi.12911","volume":"10","author":"B Ahr\u00e9n","year":"2019","unstructured":"Ahr\u00e9n B (2019) Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig 10:196\u2013201. https:\/\/doi.org\/10.1111\/jdi.12911","journal-title":"J Diabetes Investig"},{"key":"2475_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/dom.14054","volume":"22","author":"TK Thethi","year":"2020","unstructured":"Thethi TK, Pratley R, Meier JJ (2020) Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metabolism 22:1263\u20131277. https:\/\/doi.org\/10.1111\/dom.14054","journal-title":"Diabetes Obes Metabolism"},{"key":"2475_CR21","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13300-024-01614-6","volume":"15","author":"S-B Catrina","year":"2024","unstructured":"Catrina S-B, Amadid H, Braae UC, Dereke J, Ekberg NR, Klanger B, Jansson S (2024) PIONEER REAL Sweden: a Multicentre, prospective, real-world observational study of oral semaglutide use in adults with type 2 diabetes in Swedish clinical practice. Diabetes Ther 15:2079\u20132095. https:\/\/doi.org\/10.1007\/s13300-024-01614-6","journal-title":"Diabetes Ther"},{"key":"2475_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/dom.15493","volume":"26","author":"AB Jain","year":"2024","unstructured":"Jain AB, Reichert SM, Amadid H, Braae UC, Bradley RM, Kim JW, Soo V, Yale J (2024) Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: a multicentre, prospective real\u2010world study (PIONEER REAL Canada). Diabetes Obes Metabolism 26:1799\u20131807. https:\/\/doi.org\/10.1111\/dom.15493","journal-title":"Diabetes Obes Metabolism"},{"key":"2475_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13300-023-01525-y","volume":"15","author":"A Kick","year":"2024","unstructured":"Kick A, M\u2019Rabet-Bensalah K, Acquistapace F, Amadid H, Amb\u00fchl RA, Braae UC, Item F, Schultes B, Z\u00fcger T, Rudofsky G (2024) Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland Multicentre, prospective, observational study. Diabetes Ther 15:623\u2013637. https:\/\/doi.org\/10.1007\/s13300-023-01525-y","journal-title":"Diabetes Ther"},{"key":"2475_CR24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s13300-024-01588-5","volume":"15","author":"W Van Houtum","year":"2024","unstructured":"Van Houtum W, Schr\u00f6mbges P, Amadid H, Van Bon AC, Braae UC, Hoogstraten C, Herrings H (2024) Real-world use of oral semaglutide in adults with type 2 diabetes in the PIONEER REAL Netherlands Multicentre, prospective, observational study. Diabetes Ther 15:1749\u20131768. https:\/\/doi.org\/10.1007\/s13300-024-01588-5","journal-title":"Diabetes Ther"},{"key":"2475_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02973-z","author":"P Saravanan","year":"2024","unstructured":"Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A (2024) PIONEER REAL UK: a Multi-centre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-024-02973-z","journal-title":"Adv Ther"},{"key":"2475_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N, Arisaka T, Asakura T, Azuma N, Fukuda S, Fukushima Y, Harada N, Inoue S, Ishida H, Ishii H, Ishikawa S, Jinnouchi H, Kaneko S, Kanno K, Kato M, Kato Y, Kawada T, Kim H, Kiyosue A, Matsuoka O, Miho O, Nakamoto S, Nakamura S, Nakanishi S, Nishimura H, Numata A, Ohama T, Okabe T, Okuguchi F, Osonoi T, Sasaki T, Seino H, Shin K, Shiraiwa T, Sugiura T, Wada S, Yamauchi A (2020) Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 8:392\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(20)30074-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2475_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsb\u00f8ll T, Warren ML, Bain SC (2019) Oral Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"2475_CR28","doi-asserted-by":"publisher","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C, Abramof R, Alpenidze D, Aronoff S, Astamirova K, Barker B, Bedel G, Belousova L, Benson M, Beshay I, Biggs W, Blaze K, Bogdanski P, Busch R, Chaidarun S, Chandran S, Chang A, Chilka S, Cleland A, Connery L, Cornett G, Delgado B, Desouza C, Donner T, Eliasson K, Eriksson J, Folkerth S, Forshaw K, Frandsen HA, Frolova E, Gandy W, Gatipon G, Golovach A, Gonzalez-Orozco L, Gumprecht J, Haddad E, Hansen TK, Hart T, Hasan S, Hella B, Heller S, Hellgren M, Hewitt M, Hietaniemi S, Hitz M, Houser P, Huntley R, Jackson R, Jakobsen PE, Kapoor A, Kargina L, Kazakova E, Khan K, Klein E, Knoble H, Krasnopeeva (Kabachkova) N, Krzeminski A, Kunitsyna M, Lawhead J, Levin K, Levin P, Lewy-Alterbaum L, Lindmark S, Lindsay R, Luts A, Lysenko T, Madsbad S, Maxwell T, Mbogua C, Mcknight J, Mets\u00e4rinne K, Milovanova T, Morawski E, Mosenzon O, Nabriski D, Nguyen H, Nicol P, Nieminen S, Nikkola A, Norwood P, O\u2019Donnell P, Odugbesan A, Parker J, Pergaeva Y, Peskov A, Plevin S, Pouzar J, Pratley R, Reed J, Rossing P, Sathyapalan T, Sergeeva-Kondrachenko M, Shaikh Z, Shamkhalova M, Shehadeh N, Shlesinger Y, Silver R, Snyder B, Soufer J, Strand J, Sulosaari S, Tirosh A, Traylor H, Uhlenius N, Vagapova G, Yanovskaya M, Zarutskaya L, Zhdanova E (2019) Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology 7:515\u2013527. https:\/\/doi.org\/10.1016\/S2213-8587(19)30192-5","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"2475_CR29","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.3390\/jcm12186052","volume":"12","author":"R Candido","year":"2023","unstructured":"Candido R, Gaiotti S, Giudici F, Toffoli B, De Luca F, Velardi V, Petrucco A, Gottardi C, Manca E, Buda I, Fabris B, Bernardi S (2023) Real-world retrospective study into the effects of oral semaglutide (as a switchover or Add-On therapy) in type 2 diabetes. JCM 12:6052. https:\/\/doi.org\/10.3390\/jcm12186052","journal-title":"JCM"},{"key":"2475_CR30","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/jcm13113054","volume":"13","author":"MPA Baldassarre","year":"2024","unstructured":"Baldassarre MPA, Di Dalmazi G, Coluzzi S, Carrieri F, Febo F, Centorame G, Cassino P, Piacentino L, Baroni MG, Consoli A, Formoso G (2024) Oral semaglutide in routine clinical practice: characteristics of people with type 2 diabetes started on the drug and changes in their clinical parameters after 24 weeks of treatment. JCM 13:3054. https:\/\/doi.org\/10.3390\/jcm13113054","journal-title":"JCM"},{"key":"2475_CR31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00592-023-02115-x","volume":"60","author":"C Berra","year":"2023","unstructured":"Berra C, Manfrini R, Mirani M, Bucciarelli L, Zakaria AS, Piccini S, Ghelardi R, Lunati ME, Rodovalho S, Bifari F, Fiorina P, Folli F (2023) AWARE a novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus. Acta Diabetol 60:1257\u20131266. https:\/\/doi.org\/10.1007\/s00592-023-02115-x","journal-title":"Acta Diabetol"},{"key":"2475_CR32","doi-asserted-by":"publisher","first-page":"107517","DOI":"10.1016\/j.phrs.2024.107517","volume":"210","author":"C Berra","year":"2024","unstructured":"Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L, Mortola U, Lunati E, Bucciarelli L, Cimino V, Folli F (2024) Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE\u2013\u20092 study. Pharmacol Res 210:107517. https:\/\/doi.org\/10.1016\/j.phrs.2024.107517","journal-title":"Pharmacol Res"},{"key":"2475_CR33","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1152\/ajpendo.00366.2002","volume":"284","author":"AM Chang","year":"2003","unstructured":"Chang AM, Halter JB (2003) Aging and insulin secretion. Am J Physiology-Endocrinology Metabolism 284:E7\u2013E12. https:\/\/doi.org\/10.1152\/ajpendo.00366.2002","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"key":"2475_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12902-024-01658-6","volume":"24","author":"Y Oe","year":"2024","unstructured":"Oe Y, Nomoto H, Cho KY, Yokozeki K, Ono T, Miya A, Kameda H, Nakamura A, Arimura Y, Atsumi T (2024) Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study). BMC Endocr Disord 24:124. https:\/\/doi.org\/10.1186\/s12902-024-01658-6","journal-title":"BMC Endocr Disord"},{"key":"2475_CR35","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s13300-024-01631-5","volume":"15","author":"G Sato","year":"2024","unstructured":"Sato G, Uchino H, Hirose T (2024) Efficacy and safety of escalating the dose of oral semaglutide from 7 to 14\u00a0mg: a Single-Center, Retrospective Observational Study. Diabetes Ther 15:2119\u20132130. https:\/\/doi.org\/10.1007\/s13300-024-01631-5","journal-title":"Diabetes Ther"},{"key":"2475_CR36","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s13300-024-01590-x","volume":"15","author":"DM Williams","year":"2024","unstructured":"Williams DM, Alberts B-A, Sharaf A, Sharaf G, Bain SC, Kalhan A, Min T (2024) Real-world clinical experience of oral semaglutide in a Secondary Diabetes Clinic in the UK: a retrospective observational study. Diabetes Ther 15:1639\u20131646. https:\/\/doi.org\/10.1007\/s13300-024-01590-x","journal-title":"Diabetes Ther"},{"key":"2475_CR37","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.3390\/jcm13164752","volume":"13","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, Ronconi V, Sguanci M, Palomares SM, Mancin S, Tartaglia FC, Cangelosi G, Petrelli F (2024) Oral semaglutide in type 2 diabetes: clinical\u2013metabolic outcomes and quality of life in real-world practice. JCM 13:4752. https:\/\/doi.org\/10.3390\/jcm13164752","journal-title":"JCM"},{"key":"2475_CR38","doi-asserted-by":"publisher","unstructured":"Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, Braae UC, Major-Pedersen A, Suzuki R (2024) PIONEER REAL Japan: primary results from a multicenter, prospective, real\u2010world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. J Diabetes Invest jdi 14291. https:\/\/doi.org\/10.1111\/jdi.14291","DOI":"10.1111\/jdi.14291"},{"key":"2475_CR39","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Das SR, Ekhlaspour L, Hilliard ME, Johnson EL, Khunti K, Kosiborod MN, Lingvay I, Matfin G, McCoy RG, Perry ML, Pilla SJ, Polsky S, Prahalad P, Pratley RE, Segal AR, Seley JJ, Stanton RC, Gabbay RA (2024) 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes\u20142024. Diabetes Care 47:S179\u2013S218. https:\/\/doi.org\/10.2337\/dc24-S010","journal-title":"Diabetes Care"},{"key":"2475_CR40","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","volume":"28","author":"AM Cebri\u00e1n-Cuenca","year":"2022","unstructured":"Cebri\u00e1n-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltr\u00e1n D, Consuegra-S\u00e1nchez L (2022) Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: data from a large Mediterranean population. Eur J Prev Cardiol 28:e32\u2013e34. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa073","journal-title":"Eur J Prev Cardiol"},{"key":"2475_CR41","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB (2023) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metabolism 25:1932\u20131941. https:\/\/doi.org\/10.1111\/dom.15058","journal-title":"Diabetes Obes Metabolism"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02475-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:02:41Z","timestamp":1757952161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02475-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2475"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02475-6","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the relevant ethics committee and adhered to the Good Clinical Practice guidelines concerning clinical investigations on human subjects and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"All participants provided written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}